Oxfam America, a Moderna shareholder, has filed a complaint against the drug company with the Securities and Exchange Commission. A lawyer for Oxfam said, “Instead of … using its life-saving technology to help curb the pandemic, Moderna is … obfuscating its patent dispute with the US government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that COVID-19 has placed on the global economy.”

In other vaccine news, European Union regulators have approved Novavax’s vaccine for people 18 and older. Tests have shown the U.S.-developed shot to be roughly 90% effective, though there is limited data on its efficacy against variants of concern, including Omicron. Novavax will start delivering vaccines to the EU in January.